Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | geminin, DNA replication inhibitor | Starlite/ChEMBL | No references |
Homo sapiens | synuclein, alpha (non A4 component of amyloid precursor) | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Brugia malayi | Hypothetical 65.5 kDa Trp-Asp repeats containing protein F02E8.5 inchromosome X | geminin, DNA replication inhibitor | 209 aa | 176 aa | 27.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.0095 | 0.3026 | 1 |
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.0095 | 0.3026 | 0.5 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0095 | 0.3026 | 0.5 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0095 | 0.3026 | 0.5 |
Trichomonas vaginalis | sulfite reductase, putative | 0.0095 | 0.3026 | 1 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.0059 | 0.0693 | 0.0693 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.0095 | 0.3026 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0205 | 1 | 1 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0095 | 0.3026 | 1 |
Echinococcus multilocularis | geminin | 0.0205 | 1 | 1 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0095 | 0.3026 | 0.5 |
Brugia malayi | flavodoxin family protein | 0.0095 | 0.3026 | 1 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.0095 | 0.3026 | 0.2506 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.0095 | 0.3026 | 0.2506 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.0095 | 0.3026 | 0.5 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.0085 | 0.2333 | 0.5 |
Mycobacterium ulcerans | formate dehydrogenase H FdhF | 0.0095 | 0.3026 | 0.5 |
Giardia lamblia | Hypothetical protein | 0.0085 | 0.2333 | 0.5 |
Leishmania major | p450 reductase, putative | 0.0095 | 0.3026 | 1 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0095 | 0.3026 | 0.5 |
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.0095 | 0.3026 | 0.5 |
Schistosoma mansoni | cytochrome P450 reductase | 0.0095 | 0.3026 | 0.3026 |
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.0095 | 0.3026 | 0.2506 |
Trypanosoma cruzi | p450 reductase, putative | 0.0095 | 0.3026 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0095 | 0.3026 | 1 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.0095 | 0.3026 | 0.2506 |
Plasmodium falciparum | nitric oxide synthase, putative | 0.0095 | 0.3026 | 0.5 |
Chlamydia trachomatis | sulfite reductase | 0.0059 | 0.0693 | 0.5 |
Brugia malayi | FAD binding domain containing protein | 0.0095 | 0.3026 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0205 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 3.2643 uM | PubChem BioAssay. A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 5.6234 uM | PubChem BioAssay. qHTS of alpha-syn Inhibitors. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 35.4813 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588856, AID588860] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.